Global Urinary System Drugs Market Research Report 2022

Global Urinary System Drugs Market Research Report 2022

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Urinary System Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Injection
1.2.3 Tablets
1.2.4 Capsule
1.2.5 Suppository
1.2.6 Granules
1.2.7 Powder
1.2.8 Pills
1.2.9 Cream
1.2.10 Others
1.3 Market by Application
1.3.1 Global Urinary System Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Kidney Disease Medication
1.3.3 Medication For Prostate Disease
1.3.4 Male Dysfunction
1.3.5 Lithotripsy Drug
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Urinary System Drugs Market Perspective (2017-2028)
2.2 Urinary System Drugs Growth Trends by Region
2.2.1 Urinary System Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Urinary System Drugs Historic Market Size by Region (2017-2022)
2.2.3 Urinary System Drugs Forecasted Market Size by Region (2023-2028)
2.3 Urinary System Drugs Market Dynamics
2.3.1 Urinary System Drugs Industry Trends
2.3.2 Urinary System Drugs Market Drivers
2.3.3 Urinary System Drugs Market Challenges
2.3.4 Urinary System Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Urinary System Drugs Players by Revenue
3.1.1 Global Top Urinary System Drugs Players by Revenue (2017-2022)
3.1.2 Global Urinary System Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Urinary System Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Urinary System Drugs Revenue
3.4 Global Urinary System Drugs Market Concentration Ratio
3.4.1 Global Urinary System Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Urinary System Drugs Revenue in 2021
3.5 Urinary System Drugs Key Players Head office and Area Served
3.6 Key Players Urinary System Drugs Product Solution and Service
3.7 Date of Enter into Urinary System Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Urinary System Drugs Breakdown Data by Type
4.1 Global Urinary System Drugs Historic Market Size by Type (2017-2022)
4.2 Global Urinary System Drugs Forecasted Market Size by Type (2023-2028)
5 Urinary System Drugs Breakdown Data by Application
5.1 Global Urinary System Drugs Historic Market Size by Application (2017-2022)
5.2 Global Urinary System Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Urinary System Drugs Market Size (2017-2028)
6.2 North America Urinary System Drugs Market Size by Country (2017-2022)
6.3 North America Urinary System Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Urinary System Drugs Market Size (2017-2028)
7.2 Europe Urinary System Drugs Market Size by Country (2017-2022)
7.3 Europe Urinary System Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Urinary System Drugs Market Size (2017-2028)
8.2 Asia-Pacific Urinary System Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Urinary System Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Urinary System Drugs Market Size (2017-2028)
9.2 Latin America Urinary System Drugs Market Size by Country (2017-2022)
9.3 Latin America Urinary System Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Urinary System Drugs Market Size (2017-2028)
10.2 Middle East & Africa Urinary System Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Urinary System Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Urinary System Drugs Introduction
11.1.4 Johnson & Johnson Revenue in Urinary System Drugs Business (2017-2022)
11.1.5 Johnson & Johnson Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Urinary System Drugs Introduction
11.2.4 Bayer Revenue in Urinary System Drugs Business (2017-2022)
11.2.5 Bayer Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Urinary System Drugs Introduction
11.3.4 Pfizer Revenue in Urinary System Drugs Business (2017-2022)
11.3.5 Pfizer Recent Development
11.4 GSK
11.4.1 GSK Company Detail
11.4.2 GSK Business Overview
11.4.3 GSK Urinary System Drugs Introduction
11.4.4 GSK Revenue in Urinary System Drugs Business (2017-2022)
11.4.5 GSK Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Detail
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Urinary System Drugs Introduction
11.5.4 Boehringer Ingelheim Revenue in Urinary System Drugs Business (2017-2022)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Urinary System Drugs Introduction
11.6.4 Roche Revenue in Urinary System Drugs Business (2017-2022)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Urinary System Drugs Introduction
11.7.4 Novartis Revenue in Urinary System Drugs Business (2017-2022)
11.7.5 Novartis Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Urinary System Drugs Introduction
11.8.4 AstraZeneca Revenue in Urinary System Drugs Business (2017-2022)
11.8.5 AstraZeneca Recent Development
11.9 Dr. Reddy's Laboratories
11.9.1 Dr. Reddy's Laboratories Company Detail
11.9.2 Dr. Reddy's Laboratories Business Overview
11.9.3 Dr. Reddy's Laboratories Urinary System Drugs Introduction
11.9.4 Dr. Reddy's Laboratories Revenue in Urinary System Drugs Business (2017-2022)
11.9.5 Dr. Reddy's Laboratories Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Urinary System Drugs Introduction
11.10.4 Mylan Revenue in Urinary System Drugs Business (2017-2022)
11.10.5 Mylan Recent Development
11.11 Sun Pharma
11.11.1 Sun Pharma Company Detail
11.11.2 Sun Pharma Business Overview
11.11.3 Sun Pharma Urinary System Drugs Introduction
11.11.4 Sun Pharma Revenue in Urinary System Drugs Business (2017-2022)
11.11.5 Sun Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Detail
11.12.2 Cipla Business Overview
11.12.3 Cipla Urinary System Drugs Introduction
11.12.4 Cipla Revenue in Urinary System Drugs Business (2017-2022)
11.12.5 Cipla Recent Development
11.13 Merck
11.13.1 Merck Company Detail
11.13.2 Merck Business Overview
11.13.3 Merck Urinary System Drugs Introduction
11.13.4 Merck Revenue in Urinary System Drugs Business (2017-2022)
11.13.5 Merck Recent Development
11.14 Cubist Pharmaceuticals
11.14.1 Cubist Pharmaceuticals Company Detail
11.14.2 Cubist Pharmaceuticals Business Overview
11.14.3 Cubist Pharmaceuticals Urinary System Drugs Introduction
11.14.4 Cubist Pharmaceuticals Revenue in Urinary System Drugs Business (2017-2022)
11.14.5 Cubist Pharmaceuticals Recent Development
11.15 Abbott Laboratories
11.15.1 Abbott Laboratories Company Detail
11.15.2 Abbott Laboratories Business Overview
11.15.3 Abbott Laboratories Urinary System Drugs Introduction
11.15.4 Abbott Laboratories Revenue in Urinary System Drugs Business (2017-2022)
11.15.5 Abbott Laboratories Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Detail
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Urinary System Drugs Introduction
11.16.4 Eli Lilly Revenue in Urinary System Drugs Business (2017-2022)
11.16.5 Eli Lilly Recent Development
11.17 Melinta Therapeutics
11.17.1 Melinta Therapeutics Company Detail
11.17.2 Melinta Therapeutics Business Overview
11.17.3 Melinta Therapeutics Urinary System Drugs Introduction
11.17.4 Melinta Therapeutics Revenue in Urinary System Drugs Business (2017-2022)
11.17.5 Melinta Therapeutics Recent Development
11.18 Sanofi
11.18.1 Sanofi Company Detail
11.18.2 Sanofi Business Overview
11.18.3 Sanofi Urinary System Drugs Introduction
11.18.4 Sanofi Revenue in Urinary System Drugs Business (2017-2022)
11.18.5 Sanofi Recent Development
11.19 Daiichi Sankyo
11.19.1 Daiichi Sankyo Company Detail
11.19.2 Daiichi Sankyo Business Overview
11.19.3 Daiichi Sankyo Urinary System Drugs Introduction
11.19.4 Daiichi Sankyo Revenue in Urinary System Drugs Business (2017-2022)
11.19.5 Daiichi Sankyo Recent Development
11.20 Lupin
11.20.1 Lupin Company Detail
11.20.2 Lupin Business Overview
11.20.3 Lupin Urinary System Drugs Introduction
11.20.4 Lupin Revenue in Urinary System Drugs Business (2017-2022)
11.20.5 Lupin Recent Development
11.21 Apogepha
11.21.1 Apogepha Company Detail
11.21.2 Apogepha Business Overview
11.21.3 Apogepha Urinary System Drugs Introduction
11.21.4 Apogepha Revenue in Urinary System Drugs Business (2017-2022)
11.21.5 Apogepha Recent Development
11.22 Astellas Pharma
11.22.1 Astellas Pharma Company Detail
11.22.2 Astellas Pharma Business Overview
11.22.3 Astellas Pharma Urinary System Drugs Introduction
11.22.4 Astellas Pharma Revenue in Urinary System Drugs Business (2017-2022)
11.22.5 Astellas Pharma Recent Development
11.23 Dr. Dunner
11.23.1 Dr. Dunner Company Detail
11.23.2 Dr. Dunner Business Overview
11.23.3 Dr. Dunner Urinary System Drugs Introduction
11.23.4 Dr. Dunner Revenue in Urinary System Drugs Business (2017-2022)
11.23.5 Dr. Dunner Recent Development
11.24 Kowa
11.24.1 Kowa Company Detail
11.24.2 Kowa Business Overview
11.24.3 Kowa Urinary System Drugs Introduction
11.24.4 Kowa Revenue in Urinary System Drugs Business (2017-2022)
11.24.5 Kowa Recent Development
11.25 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
11.25.1 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Company Detail
11.25.2 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Business Overview
11.25.3 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Urinary System Drugs Introduction
11.25.4 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022)
11.25.5 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Development
11.26 Tianjin Tongrentang Group
11.26.1 Tianjin Tongrentang Group Company Detail
11.26.2 Tianjin Tongrentang Group Business Overview
11.26.3 Tianjin Tongrentang Group Urinary System Drugs Introduction
11.26.4 Tianjin Tongrentang Group Revenue in Urinary System Drugs Business (2017-2022)
11.26.5 Tianjin Tongrentang Group Recent Development
11.27 Jiangsu Hengrui Pharmaceutical
11.27.1 Jiangsu Hengrui Pharmaceutical Company Detail
11.27.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.27.3 Jiangsu Hengrui Pharmaceutical Urinary System Drugs Introduction
11.27.4 Jiangsu Hengrui Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022)
11.27.5 Jiangsu Hengrui Pharmaceutical Recent Development
11.28 Hunan Qianjin Xiang River Pharmaceutical
11.28.1 Hunan Qianjin Xiang River Pharmaceutical Company Detail
11.28.2 Hunan Qianjin Xiang River Pharmaceutical Business Overview
11.28.3 Hunan Qianjin Xiang River Pharmaceutical Urinary System Drugs Introduction
11.28.4 Hunan Qianjin Xiang River Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022)
11.28.5 Hunan Qianjin Xiang River Pharmaceutical Recent Development
11.29 Kunming Jida Pharmaceutical
11.29.1 Kunming Jida Pharmaceutical Company Detail
11.29.2 Kunming Jida Pharmaceutical Business Overview
11.29.3 Kunming Jida Pharmaceutical Urinary System Drugs Introduction
11.29.4 Kunming Jida Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022)
11.29.5 Kunming Jida Pharmaceutical Recent Development
11.30 Jiangsu Lianhuan Pharmaceutical
11.30.1 Jiangsu Lianhuan Pharmaceutical Company Detail
11.30.2 Jiangsu Lianhuan Pharmaceutical Business Overview
11.30.3 Jiangsu Lianhuan Pharmaceutical Urinary System Drugs Introduction
11.30.4 Jiangsu Lianhuan Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022)
11.30.5 Jiangsu Lianhuan Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Urinary System Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Injection
Table 3. Key Players of Tablets
Table 4. Key Players of Capsule
Table 5. Key Players of Suppository
Table 6. Key Players of Granules
Table 7. Key Players of Powder
Table 8. Key Players of Pills
Table 9. Key Players of Cream
Table 10. Key Players of Others
Table 11. Global Urinary System Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 12. Global Urinary System Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 13. Global Urinary System Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 14. Global Urinary System Drugs Market Share by Region (2017-2022)
Table 15. Global Urinary System Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 16. Global Urinary System Drugs Market Share by Region (2023-2028)
Table 17. Urinary System Drugs Market Trends
Table 18. Urinary System Drugs Market Drivers
Table 19. Urinary System Drugs Market Challenges
Table 20. Urinary System Drugs Market Restraints
Table 21. Global Urinary System Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 22. Global Urinary System Drugs Market Share by Players (2017-2022)
Table 23. Global Top Urinary System Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urinary System Drugs as of 2021)
Table 24. Ranking of Global Top Urinary System Drugs Companies by Revenue (US$ Million) in 2021
Table 25. Global 5 Largest Players Market Share by Urinary System Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Urinary System Drugs Product Solution and Service
Table 28. Date of Enter into Urinary System Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Urinary System Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 31. Global Urinary System Drugs Revenue Market Share by Type (2017-2022)
Table 32. Global Urinary System Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 33. Global Urinary System Drugs Revenue Market Share by Type (2023-2028)
Table 34. Global Urinary System Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 35. Global Urinary System Drugs Revenue Market Share by Application (2017-2022)
Table 36. Global Urinary System Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 37. Global Urinary System Drugs Revenue Market Share by Application (2023-2028)
Table 38. North America Urinary System Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Urinary System Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Urinary System Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 41. Europe Urinary System Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 42. Asia-Pacific Urinary System Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 43. Asia-Pacific Urinary System Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 44. Latin America Urinary System Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 45. Latin America Urinary System Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 46. Middle East & Africa Urinary System Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 47. Middle East & Africa Urinary System Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 48. Johnson & Johnson Company Detail
Table 49. Johnson & Johnson Business Overview
Table 50. Johnson & Johnson Urinary System Drugs Product
Table 51. Johnson & Johnson Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 52. Johnson & Johnson Recent Development
Table 53. Bayer Company Detail
Table 54. Bayer Business Overview
Table 55. Bayer Urinary System Drugs Product
Table 56. Bayer Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 57. Bayer Recent Development
Table 58. Pfizer Company Detail
Table 59. Pfizer Business Overview
Table 60. Pfizer Urinary System Drugs Product
Table 61. Pfizer Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 62. Pfizer Recent Development
Table 63. GSK Company Detail
Table 64. GSK Business Overview
Table 65. GSK Urinary System Drugs Product
Table 66. GSK Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 67. GSK Recent Development
Table 68. Boehringer Ingelheim Company Detail
Table 69. Boehringer Ingelheim Business Overview
Table 70. Boehringer Ingelheim Urinary System Drugs Product
Table 71. Boehringer Ingelheim Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 72. Boehringer Ingelheim Recent Development
Table 73. Roche Company Detail
Table 74. Roche Business Overview
Table 75. Roche Urinary System Drugs Product
Table 76. Roche Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 77. Roche Recent Development
Table 78. Novartis Company Detail
Table 79. Novartis Business Overview
Table 80. Novartis Urinary System Drugs Product
Table 81. Novartis Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 82. Novartis Recent Development
Table 83. AstraZeneca Company Detail
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Urinary System Drugs Product
Table 86. AstraZeneca Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Dr. Reddy's Laboratories Company Detail
Table 89. Dr. Reddy's Laboratories Business Overview
Table 90. Dr. Reddy's Laboratories Urinary System Drugs Product
Table 91. Dr. Reddy's Laboratories Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 92. Dr. Reddy's Laboratories Recent Development
Table 93. Mylan Company Detail
Table 94. Mylan Business Overview
Table 95. Mylan Urinary System Drugs Product
Table 96. Mylan Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 97. Mylan Recent Development
Table 98. Sun Pharma Company Detail
Table 99. Sun Pharma Business Overview
Table 100. Sun Pharma Urinary System DrugsProduct
Table 101. Sun Pharma Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 102. Sun Pharma Recent Development
Table 103. Cipla Company Detail
Table 104. Cipla Business Overview
Table 105. Cipla Urinary System DrugsProduct
Table 106. Cipla Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 107. Cipla Recent Development
Table 108. Merck Company Detail
Table 109. Merck Business Overview
Table 110. Merck Urinary System DrugsProduct
Table 111. Merck Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 112. Merck Recent Development
Table 113. Cubist Pharmaceuticals Company Detail
Table 114. Cubist Pharmaceuticals Business Overview
Table 115. Cubist Pharmaceuticals Urinary System DrugsProduct
Table 116. Cubist Pharmaceuticals Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 117. Cubist Pharmaceuticals Recent Development
Table 118. Abbott Laboratories Company Detail
Table 119. Abbott Laboratories Business Overview
Table 120. Abbott Laboratories Urinary System DrugsProduct
Table 121. Abbott Laboratories Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 122. Abbott Laboratories Recent Development
Table 123. Eli Lilly Company Detail
Table 124. Eli Lilly Business Overview
Table 125. Eli Lilly Urinary System DrugsProduct
Table 126. Eli Lilly Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 127. Eli Lilly Recent Development
Table 128. Melinta Therapeutics Company Detail
Table 129. Melinta Therapeutics Business Overview
Table 130. Melinta Therapeutics Urinary System DrugsProduct
Table 131. Melinta Therapeutics Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 132. Melinta Therapeutics Recent Development
Table 133. Sanofi Company Detail
Table 134. Sanofi Business Overview
Table 135. Sanofi Urinary System DrugsProduct
Table 136. Sanofi Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 137. Sanofi Recent Development
Table 138. Daiichi Sankyo Company Detail
Table 139. Daiichi Sankyo Business Overview
Table 140. Daiichi Sankyo Urinary System DrugsProduct
Table 141. Daiichi Sankyo Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 142. Daiichi Sankyo Recent Development
Table 143. Lupin Company Detail
Table 144. Lupin Business Overview
Table 145. Lupin Urinary System DrugsProduct
Table 146. Lupin Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 147. Lupin Recent Development
Table 148. Apogepha Company Detail
Table 149. Apogepha Business Overview
Table 150. Apogepha Urinary System DrugsProduct
Table 151. Apogepha Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 152. Apogepha Recent Development
Table 153. Astellas Pharma Company Detail
Table 154. Astellas Pharma Business Overview
Table 155. Astellas Pharma Urinary System DrugsProduct
Table 156. Astellas Pharma Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 157. Astellas Pharma Recent Development
Table 158. Dr. Dunner Company Detail
Table 159. Dr. Dunner Business Overview
Table 160. Dr. Dunner Urinary System DrugsProduct
Table 161. Dr. Dunner Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 162. Dr. Dunner Recent Development
Table 163. Kowa Company Detail
Table 164. Kowa Business Overview
Table 165. Kowa Urinary System DrugsProduct
Table 166. Kowa Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 167. Kowa Recent Development
Table 168. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Company Detail
Table 169. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Business Overview
Table 170. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Urinary System DrugsProduct
Table 171. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 172. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Development
Table 173. Tianjin Tongrentang Group Company Detail
Table 174. Tianjin Tongrentang Group Business Overview
Table 175. Tianjin Tongrentang Group Urinary System DrugsProduct
Table 176. Tianjin Tongrentang Group Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 177. Tianjin Tongrentang Group Recent Development
Table 178. Jiangsu Hengrui Pharmaceutical Company Detail
Table 179. Jiangsu Hengrui Pharmaceutical Business Overview
Table 180. Jiangsu Hengrui Pharmaceutical Urinary System DrugsProduct
Table 181. Jiangsu Hengrui Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 182. Jiangsu Hengrui Pharmaceutical Recent Development
Table 183. Hunan Qianjin Xiang River Pharmaceutical Company Detail
Table 184. Hunan Qianjin Xiang River Pharmaceutical Business Overview
Table 185. Hunan Qianjin Xiang River Pharmaceutical Urinary System DrugsProduct
Table 186. Hunan Qianjin Xiang River Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 187. Hunan Qianjin Xiang River Pharmaceutical Recent Development
Table 188. Kunming Jida Pharmaceutical Company Detail
Table 189. Kunming Jida Pharmaceutical Business Overview
Table 190. Kunming Jida Pharmaceutical Urinary System DrugsProduct
Table 191. Kunming Jida Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 192. Kunming Jida Pharmaceutical Recent Development
Table 193. Jiangsu Lianhuan Pharmaceutical Company Detail
Table 194. Jiangsu Lianhuan Pharmaceutical Business Overview
Table 195. Jiangsu Lianhuan Pharmaceutical Urinary System DrugsProduct
Table 196. Jiangsu Lianhuan Pharmaceutical Revenue in Urinary System Drugs Business (2017-2022) & (US$ Million)
Table 197. Jiangsu Lianhuan Pharmaceutical Recent Development
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Urinary System Drugs Market Share by Type: 2021 VS 2028
Figure 2. Injection Features
Figure 3. Tablets Features
Figure 4. Capsule Features
Figure 5. Suppository Features
Figure 6. Granules Features
Figure 7. Powder Features
Figure 8. Pills Features
Figure 9. Cream Features
Figure 10. Others Features
Figure 11. Global Urinary System Drugs Market Share by Application in 2021 & 2028
Figure 12. Kidney Disease Medication Case Studies
Figure 13. Medication For Prostate Disease Case Studies
Figure 14. Male Dysfunction Case Studies
Figure 15. Lithotripsy Drug Case Studies
Figure 16. Others Case Studies
Figure 17. Urinary System Drugs Report Years Considered
Figure 18. Global Urinary System Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 19. Global Urinary System Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 20. Global Urinary System Drugs Market Share by Region: 2021 VS 2028
Figure 21. Global Urinary System Drugs Market Share by Players in 2021
Figure 22. Global Top Urinary System Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urinary System Drugs as of 2021)
Figure 23. The Top 10 and 5 Players Market Share by Urinary System Drugs Revenue in 2021
Figure 24. North America Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. North America Urinary System Drugs Market Share by Country (2017-2028)
Figure 26. United States Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Canada Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Europe Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Europe Urinary System Drugs Market Share by Country (2017-2028)
Figure 30. Germany Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. France Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. U.K. Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Italy Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Russia Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Nordic Countries Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Asia-Pacific Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Urinary System Drugs Market Share by Region (2017-2028)
Figure 38. China Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Latin America Urinary System Drugs Market Share by Country (2017-2028)
Figure 46. Mexico Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Urinary System Drugs Market Share by Country (2017-2028)
Figure 50. Turkey Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Saudi Arabia Urinary System Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Johnson & Johnson Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 53. Bayer Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 54. Pfizer Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 55. GSK Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 56. Boehringer Ingelheim Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 57. Roche Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 58. Novartis Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 59. AstraZeneca Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 60. Dr. Reddy's Laboratories Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 61. Mylan Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 62. Sun Pharma Revenue Growth Rate in Urinary System Drugs Business (2017-2022)
Figure 63. Cipla Revenue Growth Rate in Urinary System Drugs B

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs